Affamed Therapeutics Drug Gets Approval

Affamed Therapeutics Drug Gets Approval

By, Admin 22 February 2024

Singapore approves AffaMed Therapeutics drug for Ocular Inflammation

Overview

New Drug Application(NDA) approved for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis China's AffaMed Therapeutics, has obtained New Drug Application (NDA) from Singapore Health Sciences Authority (HSA) for DEXTENZA® (0.4 mg dexamethasone ophthalmic insert) for the treatment of ocular inflammation and pain following ophthalmic surgery, and ocular itching associated with allergic conjunctivitis.

DEXTENZA Uses

DEXTENZA is approved in the U.S. and listed in Macau for the treatment of ocular inflammation and pain following ophthalmic surgery, and ocular itching associated with allergic conjunctivitis.

AffaMed’s Novel Product

• AffaMed is developing DEXTENZA, the first physician-administered sustained-release intracanalicular insert available to patients in ASEAN countries and Greater China. 

• DEXTENZA delivers a preservative-free dose of dexamethasone for up to 30 days with a single administration, thereby offering patients significant benefit and convenience versus current treatments which require multiple administrations of eye-drops per day.

Words from AffaMed.

"As the first NDA filing by AffaMed, the acceptance of our DEXTENZA NDA in Singapore represents an important milestone in our company's journey to successfully advance much-needed therapeutic candidates through regulatory pathways across multiple regions in Asia,"" said Vijay Karwal, Chief Executive Officer of AffaMed. 

Saferty & Efficacy Study

AffaMed has initiated a registrational trial in Mainland China to evaluate the safety and efficacy of DEXTENZA versus a placebo vehicle in the treatment of inflammation and pain following cataract surgery, and anticipates sharing topline data from this study in Q3 2024.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!